A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients

Completed

Conditions studied: Dry Eye Syndrome

In brief

A retrospective analysis of Restasis® benefits in dry eye contact lens patients.

Key facts

Study ID

NCT02522312

Run by

Hazleton Eye Specialists

People needed

102

Starts

2015-09-01

Expected to finish

2015-12-01

Last updated by the study team

2016-03-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or Female, > or = 18 years of age
• Subject was previously diagnosed (prior to Baseline Visit) with mild to severe dry eye disease (ITF level 1, 2 or 3) which required continuous medical therapy with Restasis® for a minimum duration of 6 months post-Baseline (Visit 1); or Subject was newly diagnosed (at Baseline Visit) with mild to severe dry eye disease (ITF level 1, 2 or 3) which required continuous medical therapy with Restasis® for a minimum duration of 6 months post-Baseline (Visit 1);
• Subject was prescribed Restasis® therapy at Baseline Visit (Visit 1) and commenced dosing immediately after Baseline Visit (Visit 1)
• Baseline Visit occured between 01 July 2012 and 01 January 2014;
• Subject had corneal staining and at least one dry eye sign (i.e., Schirmer's Test score <10 mm, decreased tear lake, TBUT <10 seconds, conjunctival staining, tear osmolarity >310 mOsmol/L
• Subject had charted tolerability and efficacy data reflecting at least one follow-up visit following Restasis® treatment initiation; and
• Subject wore contact lens(es) concurrently while receiving Restasis® treatment for a minimum duration of 6 months post-Baseline (Visit 1)

Where it is running

• Hazleton Eye Specialists — Hazleton, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.